» Articles » PMID: 17498893

Comparative Quantification of the in Vitro Activity of Veterinary Fluoroquinolones

Overview
Journal Vet Microbiol
Date 2007 May 15
PMID 17498893
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to compare the in vitro antimicrobial activity of the veterinary fluoroquinolones against a panel of recently isolated porcine and bovine bacterial pathogens. The study used enrofloxacin as a benchmark against which other agents were compared, being the most common fluoroquinolone used in treatment of bovine and porcine infections. The activity of ciprofloxacin was also assessed as it is the main metabolite of enrofloxacin in cattle. Enrofloxacin and ciprofloxacin generally showed higher antibacterial activity, in terms of MIC(50) values, for most pathogen species when compared with marbofloxacin, difloxacin, danofloxacin and norfloxacin. Ciprofloxacin showed significantly greater in vitro antibacterial activity than enrofloxacin against M. haemolytica, P. multocida and E. coli, whereas enrofloxacin showed greater activity than ciprofloxacin against S. aureus. Marbofloxacin was significantly more active than enrofloxacin against M. haemolytica, E. coli and B. bronchiseptica but less active against P. multocida, S. aureus, coagulase negative Staphylococci, S. dysgalactiae, S. uberis, A. pleuropneumoniae and S. suis. Danofloxacin was significantly less active than enrofloxacin against P. multocida, E. coli, S. uberis, A. pleuropneumoniae and S. suis. Enrofloxacin and its metabolite ciprofloxacin showed the highest in vitro activities against most bovine pathogens tested and the porcine pathogens also showed a high degree of sensitivity to enrofloxacin. These data facilitate further pharmacokinetic/pharmacodynamic comparison of fluoroquinolones currently used in veterinary medicine.

Citing Articles

Pradofloxacin Minimum Inhibitory Concentration Profiling of Isolates: Insights into Antimicrobial Susceptibility in Swine.

Risser J, Tessman R, Bade D, Sahin O, Clavijo M, Dhup S Pathogens. 2025; 14(1.

PMID: 39861050 PMC: 11768269. DOI: 10.3390/pathogens14010088.


Could traces of fluoroquinolones in food induce ciprofloxacin resistance in and ? An study in with important implications for maximum residue limits in food.

Gestels Z, Baranchyk Y, Van den Bossche D, Laumen J, Abdellati S, Xavier B Microbiol Spectr. 2024; 12(6):e0359523.

PMID: 38687060 PMC: 11237748. DOI: 10.1128/spectrum.03595-23.


High carriage of plasmid-mediated quinolone resistance (PMQR) genes by ESBL-producing and fluoroquinolone-resistant Escherichia coli recovered from animal waste dumps.

Joel E, Akinlabi O, Olaposi A, Olowomofe T, Adekanmbi A Mol Biol Rep. 2024; 51(1):424.

PMID: 38491992 DOI: 10.1007/s11033-024-09228-8.


Cu-Doped Hollow Bioactive Glass Nanoparticles for Bone Infection Treatment.

Jimenez-Holguin J, Sanchez-Salcedo S, Cicuendez M, Vallet-Regi M, Salinas A Pharmaceutics. 2022; 14(4).

PMID: 35456679 PMC: 9027665. DOI: 10.3390/pharmaceutics14040845.


Comparative Study on Pharmacokinetics of Four Long-Acting Injectable Formulations of Enrofloxacin in Pigs.

Ahmad S, Sun J, Cheng F, Li B, Arbab S, Zhou X Front Vet Sci. 2021; 7:604628.

PMID: 33575278 PMC: 7870480. DOI: 10.3389/fvets.2020.604628.